Safety and efficacy of Vonoprazan-based triple therapy against Helicobacter pylori infection: A single-center experience with 1118 patients

被引：9

作者：

Fukuda, Daisuke ^{[2
]}

Akazawa, Yuko ^{[1
]}

Takeshima, Fuminao ^{[1
]}

Nakao, Kazuhiko ^{[1
]}

Fukuda, Yutaka ^{[2
]}

机构：

[1] Nagasaki Univ Hosp, Div Gastroenterol & Hepatol, 1-7-1 Sakamoto, Nagasaki 8528562, Japan

[2] Fukuda Yutaka Surg Clin, Nagasaki, Japan

来源：

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY | 2016年 / 9卷 / 05期

关键词：

D O I：

10.1177/1756283X16654499

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：747 / 748

页数：2

共 5 条

[1] Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis [J].

Ashida, K. ;

Sakurai, Y. ;

Hori, T. ;

Kudou, K. ;

Nishimura, A. ;

Hiramatsu, N. ;

Umegaki, E. ;

Iwakiri, K. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 43 (02) :240-251

[2] Vonoprazan: First Global Approval [J].

Garnock-Jones, Karly P. .

DRUGS, 2015, 75 (04) :439-443

[3] Efficacy of vonoprazan-based second-line Helicobacter pylori eradication therapy in patients for whom vonoprazan-based first-line treatment failed [J].

Katayama, Yasumi ;

Toyoda, Kouji ;

Kusano, Yuumi ;

Suda, Toshikuni ;

Adachi, Shogo ;

Terauchi, Itsuo ;

Oka, Shigeki ;

Takahashi, Morio ;

Tamano, Masaya .

GUT, 2017, 66 (04) :752-753

[4]

Murakami K, 2016, GUT, DOI [10.1136/gutjnl-2015-311304, DOI 10.1136/GUTJNL-2015-311304]

[5]

Park JY GE., 2014, IARC WORKING GROUP R, P1

← 1 →